1108 South Wolcott Street, Casper, WY 82601, USA.
Immunol Allergy Clin North Am. 2020 Nov;40(4):687-700. doi: 10.1016/j.iac.2020.06.008. Epub 2020 Sep 12.
Allergic diseases represent some of the most chronic and costly chronic conditions. Medical management may require long-term pharmacotherapy, which is often associated with poor adherence. Although medications provide symptomatic control, they do not modify the allergic disease. Patients may prefer disease-modifying treatments that provide lasting benefits after discontinuation. To date, allergy immunotherapy is the only proved disease modification therapy associated with lasting benefits after discontinuation. However, allergy immunotherapy safety and efficacy has only been established in allergic rhinitis, mild to moderate asthma, and some patients with atopic dermatitis.
过敏疾病是一些最常见和最昂贵的慢性疾病。医学治疗可能需要长期的药物治疗，而药物治疗常常与较差的依从性相关。尽管药物可以提供症状控制，但它们并不能改变过敏疾病。患者可能更倾向于使用能在停药后提供持久获益的疾病修正治疗药物。迄今为止，过敏免疫疗法是唯一被证实的能在停药后提供持久获益的疾病修正治疗方法。然而，过敏免疫疗法的安全性和疗效仅在过敏性鼻炎、轻中度哮喘和一些特应性皮炎患者中得到确立。
